Risk of depression and anxiety in 7.302 patients with sarcoidosis: a nationwide cohort study

Main Article Content

Melina Gade Sikjær
Ole Hilberg
Ingeborg Farver-Vestergaard
Rikke Ibsen
Anders Løkke


sarcoidosis, Depression, Anxiety, Comorbidity, Antidepressive agents


Background and aim: The aim was to investigate the association between sarcoidosis and anxiety and/or depression (A/D) in patients with sarcoidosis and comparators matched on age, gender, residency, and cohabitation status. Methods: Patients with newly diagnosed sarcoidosis between 2001 and 2015 were identified in the Danish National Patient Register. Cases were matched 1:4 with non-sarcoidosis comparators. We estimated the cumulative incidence of A/D using the Cumulative Incidence Function and the subdistribution hazard ratio (sHR) for A/D using the Fine-Gray subdistribution hazard model. Estimates were adjusted for socio-economic status and Deyo-Charlson Comorbidity Index. Results: We identified 7.302 cases and 26.145 matched comparators. The cumulative incidence of A/D after five years was 6.0% (95%CI 5.5-6.4) for cases and 4.2% (95%CI 4.0-4.4) for matched comparators. The cumulative incidence was higher among cases for both males and females and in all age-groups compared with the matched comparators. The adjusted-sHR for A/D was 1.38 (95%CI 1.24-1.53). The adjusted-sHR for A/D was 1.51 (95%CI 1.30-1.75) for male cases and 1.25 (95%CI 1.08-1.45) for female cases compared with the matched comparators. The adjusted-sHR for A/D was higher for cases in all age-groups compared with the matched comparators, although not statistically significant among cases aged 30-39 years (a-sHR 1.15; 95%CI 0.92-1.44). Conclusions: Sarcoidosis cases had a higher risk of A/D compared with matched comparators during 18 years of follow-up. The risk of developing A/D was greater for male and female cases and within all age-groups compared with the matched comparators.

Abstract 236 | PDF Downloads 188


1. Grunewald J, Grutters JC, Arkema EV, et al. Sarcoidosis. Nature reviews Disease primers. 2019;5(1):45.
2. Valeyre D, Bernaudin JF, Uzunhan Y, et al. Clinical presentation of sarcoidosis and diagnostic work-up. Semin Respir Crit Care Med. 2014;35(3):336-51.
3. Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389-402.
4. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155-67.
5. Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of Sarcoidosis. Clin Chest Med. 2015;36(4):727-37.
6. Thunold RF, Løkke A, Cohen AL, Ole H, Bendstrup E. Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):2-17.
7. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329-34.
8. Harper LJ, Gerke AK, Wang XF, et al. Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. Am J Respir Crit Care Med. 2020;201(8):955-64.
9. Sharp M, Brown T, Chen E, Rand CS, Moller DR, Eakin MN. Psychological burden associated with worse clinical outcomes in sarcoidosis. BMJ open respiratory research. 2019;6(1):e000467.
10. Holas P, Krejtz I, Urbankowski T, Skowyra A, Ludwiniak A, Domagala-Kulawik J. Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):282-8.
11. Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):139-46.
12. Ireland J, Wilsher M. Perceptions and beliefs in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(1):36-42.
13. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008;30(5):441-5.
14. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997-1004.
15. de Kleijn WP, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013;18(2):439-52.
16. Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study. Respir Med. 2018;138s:S24-s30.
17. Bosse-Henck A, Koch R, Wirtz H, Hinz A. Fatigue and Excessive Daytime Sleepiness in Sarcoidosis: Prevalence, Predictors, and Relationships between the Two Symptoms. Respiration. 2017;94(2):186-97.
18. Sikjaer MG, Lokke A, Hilberg O. The influence of psychiatric disorders on the course of lung cancer, chronic obstructive pulmonary disease and tuberculosis. Respir Med. 2018;135:35-41.
19. Pedersen CB. The Danish Civil Registration System. Scandinavian journal of public health. 2011;39(7 Suppl):22-5.
20. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-9.
21. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-90.
22. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scandinavian journal of public health. 2011;39(7 Suppl):103-5.
23. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scandinavian journal of public health. 2011;39(7 Suppl):38-41.
24. Dansk Selskab for Almen Medicin. Angsttilstande 2010 [Available from: https://vejledninger.dsam.dk/angst/?mode=visKapitel&cid=58&gotoChapter=58.
25. Medicin DSfA. Unipolar depression 2010 [Available from: https://vejledninger.dsam.dk/depression/.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
27. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
28. Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391-400.
29. de Boer S, Kolbe J, Wilsher ML. The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology. 2014;19(7):1019-24.
30. Balaji AL, Abhishekh HA, Kumar NC. Depression in sarcoidosis patients of a tertiary care general hospital. Aust N Z J Psychiatry. 2012;46(12):1199-200.
31. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147-53.
32. Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15(1):59-66.
33. Marrie RA, Walld R, Bolton JM, et al. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. J Psychosom Res. 2017;101:17-23.
34. Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J. 1999;13(4):718-22.
35. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(2):127-36.
36. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190(S7):S54-60.
37. Gade Sikjær M, Hilberg O, Ibsen R, Bock K, Løkke A. Direct and indirect economic and health consequences related to sarcoidosis in Denmark: A national register-based study. Respir Med. 2019;152:7-13.
38. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897-910.
39. Piccinelli M, Wilkinson G. Gender differences in depression. Critical review. Br J Psychiatry. 2000;177:486-92.
40. The Danish Health Athority. Laveste antal brugere af antidepressiv medicin de seneste 10 år 2017 [Available from: https://sundhedsdatastyrelsen.dk.
41. The Danish Health Athority. Færre starter i behandling med antidepressiv medicin 2017 [Available from: https://sundhedsdatastyrelsen.dk/.
42. Abbing-Karahagopian V, Huerta C, Souverein PC, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. 2014;70(7):849-57.